Johnson & Johnson $JNJ Stock Sold by Prime Capital Investment Advisors LLC

Key Points

• Prime Capital Investment Advisors LLC reduced its Johnson & Johnson stake by 3.2% in the third quarter, selling 4,024 shares and retaining 123,213 shares valued at approximately $32.6 million. Institutional investors own 69.55% of J&J.
• Johnson & Johnson reported quarterly adjusted EPS of $2.59, exceeding estimates, while revenue rose 5.9% year over year to $25.40 billion. The company maintained 2026 adjusted EPS guidance of $11.05–$11.15 and announced a quarterly dividend of $1.34, yielding about 2.1%.
• Insiders sold 64,515 shares worth approximately $17.3 million during the quarter. Despite mixed analyst actions, J&J retains a “Moderate Buy” consensus rating with an average price target of $275.92.

Prime Capital Investment Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,213 shares of the company's stock after selling 4,024 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Johnson & Johnson were worth $32,619,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares during the period. Deutsche Bank AG boosted its position in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares during the period. Amundi boosted its position in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares during the period. Jupiter Topco LLC bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $1,967,399,000. Finally, Janus Henderson Group PLC increased its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock worth $1,924,323,000 after purchasing an additional 148,497 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.7%

Shares of JNJ opened at $257.64 on Thursday. The business's 50 day moving average is $265.46 and its 200 day moving average is $249.94. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The company has a market capitalization of $620.90 billion, a PE ratio of 39.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the company posted $2.80 EPS. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is 81.21%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson raised its 2026 outlook, calling for approximately $101.2 billion in sales at the midpoint and adjusted earnings per share of $11.05–$11.15. Its latest quarter also modestly exceeded expectations, with adjusted EPS of $2.59 versus the $2.53 consensus and revenue of $25.40 billion. Johnson & Johnson Drugs Lift Guidance, but Is 23 Times Earnings Fair?
• Positive Sentiment: The company extended its dividend-growth streak to 64 consecutive years, supporting its appeal to income-focused investors despite weaker reported earnings. Johnson & Johnson’s Profit Fell 96% Year-Over-Year
• Positive Sentiment: MedTech momentum includes the U.S. launch of the Shockwave C2 Aero Fly coronary IVL catheter, designed to reduce treatment time and strengthen J&J’s cardiovascular-device franchise. TD Cowen reiterated a Buy rating with a $300 price target. Johnson & Johnson Launches Next-Generation Shockwave Catheter

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a research report on Thursday, October 15th. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 14th. Leerink Partners dropped their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. Finally, Erste Group Bank lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.